Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial by Philip J Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Jürgen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Evie Maria Delicha, Shephard Mpofu, Luminita Pricop

“…Exposure-adjusted incidence rates for selected adverse events per 100 patient-years (secukinumab 150/75 mg) were serious infections (1.7/1.6), Candida infections (1.4/0.7), Crohn’s disease (0/0.3), ulcerative colitis (0/0.3) and major adverse cardiac events (0.3/0.8).Conclusion Subcutaneous secukinumab provided sustained improvements in the signs and symptoms, quality of life and physical function of patients with active PsA with low rate of radiographic disease progression through 3 years. …”
Get full text

A new strategy for pharmacodynamic substance screening and research on gut microbiota pathway mechanisms based on UPLC-Q-orbitrap-MS and 16S rRNA by Zhiying Yu, Tong Li, Jie Yang, Jianghua He, Weijiang Zhang, Siyuan Li, Yunpeng Qi, Yihui Yin, Ling Dong, Wenjuan Xu

“…Methods: The pharmacodynamics of Gegen Qinlian decoction (GQD) were assessed using a mouse model of dextran sulfate sodium-induced ulcerative colitis (UC). Ultra-performance liquid chromatography-quadrupole-orbitrap mass spectrometer was used to identify the prototype and metabolic components of GQD in the colon during UC. …”
Get full text

Mendelian Randomization Reveals Potential Causal Relationships Between DNA Damage Repair-Related Genes and Inflammatory Bowel Disease by Zhihao Qi, Quan Li, Shuhua Yang, Chun Fu, Burong Hu

“…The GWAS summarized data for IBD and its two subtypes, Crohn’s disease (CD) and ulcerative colitis (UC), were acquired from the FinnGen study. …”
Get full text

Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients by Alan D. Kaye, Shivam S. Shah, Coplen D. Johnson, Adalyn S. De Witt, Austin S. Thomassen, Charles P. Daniel, Shahab Ahmadzadeh, Sridhar Tirumala, Kristin Nicole Bembenick, Adam M. Kaye, Sahar Shekoohi

“…Mycophenolate, a reversible inhibitor of inosine monophosphate dehydrogenase, frequently causes gastrointestinal disturbances, including diarrhea and colitis, as well as hematologic side effects like anemia and leukopenia, which increase infection risk. …”
Get full text

Dietary Chitosan Supplementation Increases Microbial Diversity and Attenuates the Severity of Citrobacter rodentium Infection in Mice by Guiping Guan, Hongbing Wang, Shuai Chen, Gang Liu, Xia Xiong, Bie Tan, Veeramuthu Duraipandiyan, Naif Abdullah Al-Dhabi, Jun Fang

“…After Citrobacter rodentium infection, the histopathology scores indicated that COS feeding resulted in less severe colitis. IL-6 and TNF-α were significantly lower in colon from COS-feeding mice than those in the control group. …”
Get full text

Development of Collagen-Based 3D Matrix for Gastrointestinal Tract-Derived Organoid Culture by Joo Hyun Jee, Dong Hyeon Lee, Jisu Ko, Soojung Hahn, Sang Yun Jeong, Han Kyung Kim, Enoch Park, Seon Young Choi, Sukin Jeong, Joong Woon Lee, Han-Jun Cho, Min-Soo Kwon, Jongman Yoo

“…When mouse colon organoids were transplanted with collagen matrix into the EDTA-colitis mouse model, colon organoids were successfully engrafted in damaged tissue. …”
Get full text

Mendelian randomization analysis does not support a causal influence between lipoprotein(A) and immune-mediated inflammatory diseases by Yun Ti, Dan Xu, Xiaoning Qin, Yang Hu, Yuru Xu, Qingzhao Zhao, Peili Bu, Jingyuan Li

“…We performed a bidirectional two-sample mendelian randomization analyses based on genome-wide association study (GWAS) summary statistics of Lp(a) and nine IMIDs, specifically celiac disease (CeD), Crohn’s disease (CD), ulcerative colitis (UC), inflammatory bowel disease (IBD), multiple sclerosis (MS), psoriasis (Pso), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), and summary-level data for lipid traits. …”
Get full text

Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protoc... by Sander W Tas, Joost Raaphorst, Paco M J Welsing, Jacob M van Laar, Rogier M Thurlings, Robbert J Goekoop, César Magro Checa, Jan A M van Laar, Bettina C Geertsema-Hoeve, Nicolle H Rekers, Erik Present

“…The Drug Rediscovery in IMIDs (DRIMID) consortium aims to conduct a prospective pilot basket trial to investigate the effects of filgotinib, a JAK1 preferential inhibitor approved for ulcerative colitis and rheumatoid arthritis, on disease activity, quality of life and safety in patients with refractory BD, IIM and IgG4-RD.Methods and analysis In this investigator-initiated, multicentre, open-label phase 2 study, up to 60 patients with rare IMIDs will be enrolled for a 26-week treatment period with filgotinib 200 mg once daily. …”
Get full text

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting syste... by Zhaohui Li, Zixiang Zhou, Nan Zhang, Binhe Tian, Xiangqi Chen, Haitao Zhao, Hanping Wang

“…Besides, the combination treatment of ICI- and KRAS-targeted drugs also increases the incidence of colitis, pulmonary embolism and dehydration.…”
Get full text

TNF-α Enhances the Therapeutic Effects of MenSC-Derived Small Extracellular Vesicles on Inflammatory Bowel Disease through Macrophage Polarization by miR-24-3p by Huikang Xu, Jiamin Fu, Lijun Chen, Sining Zhou, Yangxin Fang, Qi Zhang, Xin Chen, Li Yuan, Yifei Li, Zhenyu Xu, Charlie Xiang

“…Hence, we explored the role of tumor necrosis factor α- (TNF-α-) pretreated MenSC-derived small EV (MenSCs-sEVTNF-α) in a mouse model of dextran sulfate sodium- (DSS-) induced colitis, expecting to find better therapeutic alterations. …”
Get full text

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system by Shiyi Wang, Xiaojian Wang, Jing Ding, Xudong Zhang, Hongmei Zhu, Yihong Fan, Changbo Sun

“…BackgroundUpadacitinib, a Janus kinase inhibitor, has been increasingly used over the past few years to treat moderate to severe ulcerative colitis and Crohn’s disease in patients who are insufficiently responsive or intolerant to tumor necrosis factor (TNF) antibodies, demonstrating notable clinical efficacy. …”
Get full text

Multi-ancestry genome-wide meta-analysis with 472,819 individuals identifies 32 novel risk loci for psoriasis by Min Zhang, Wenting Su, Jiahui Deng, Bin Zhai, Gaizhi Zhu, Ran Gao, Qi Zeng, Jinming Qiu, Ziqing Bian, He Xiao, Guoming Luan, Renxi Wang

“…Gene-set analyses and the genetic correlation revealed that psoriasis-related genes have the positive correlations with autoimmune diseases such as ulcerative colitis, inflammatory bowel diseases, and Crohn’s disease. …”
Get full text

CMV Pancreatitis in an Immunocompromised Patient by Jaffer Ahmad, Najia Sayedy, Raghavendra Sanivarapu, Jagadish Akella, Javed Iqbal

“…ED vitals showed a sepsis picture with fever, tachycardia, low white blood cell (WBC) count with bandemia, and CT scan showing acute pancreatitis, cholelithiasis, gastritis, and colitis. The patient denied alcohol use and MRCP showed no stone impaction. …”
Get full text

Fecal Microbiota Transplantation: A Systematic Review of Therapeutic Potential, Preparation Techniques, and Delivery Methods Across Medical Conditions by Syamand Ahmed Qadir, Qausar Hamed ALKaisy, Abdulbasit F. Hasan, Farhang Hameed Awlqadr, Ammar B. Altemimi, Aryan Mahmood Faraj, Angelo Maria Giuffrè, Mohammed N. Saeed, Sherzad Rasul Abdalla

“…FMT’s applications are expanding to inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, as well as metabolic disorders and neuropsychiatric conditions. …”
Get full text

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer by Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

“…Common Grade ≥ 3 AEs included pneumonitis, elevated aspartate transaminase, elevated alanine transaminase, adrenal insufficiency, and colitis. No treatment-related deaths were reported. …”
Get full text

Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease by Tetsuhiro Yoshimura, Keiichi Mitsuyama, Ryosuke Sakemi, Hidetoshi Takedatsu, Shinichiro Yoshioka, Kotaro Kuwaki, Atsushi Mori, Shuhei Fukunaga, Toshihiro Araki, Masaru Morita, Kozo Tsuruta, Hiroshi Yamasaki, Takuji Torimura

“…Studies on serum leucine-rich alpha-2 glycoprotein (LRG) in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are scarce; the methods for estimating disease activity are less established, particularly for CD. …”
Get full text

Risk factors for Clostridioides difficile infection among patients diagnosed with inflammatory intestinal and rheumatological diseases in the biologic era by Helena Martínez-Lozano, Paula Saralegui-Gonzalez, Elena Reigadas, Pablo Ramón Fueyo-Peláez, Aurea García-García, José Miranda-Bautista, Luis Alcalá, Juan Carlos Nieto, María Elena Lobato-Matilla, Ignacio Marín-Jiménez, Patricia Muñoz, Luis Menchén

“…Within the IBD-cohort, patients with ulcerative colitis had an increased risk for CDI compared to Crohn’s disease (OR:2.00, 95% CI: 1.18–3.42, p = 0.011). …”
Get full text

Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab by Anne Rogiers, Christophe Leys, Justine Lauwyck, Adrian Schembri, Gil Awada, Julia Katharina Schwarze, Jennifer De Cremer, Peter Theuns, Paul Maruff, Mark De Ridder, Jan L. Bernheim, Bart Neyns

“…All cases of skin toxicity (N=8), hepatitis (N=1), colitis (N=3), and sarcoidosis (N=1) resolved without impact on HRQoL. …”
Get full text

Toward Enteral Nutrition in the Treatment of Pediatric Crohn Disease in Canada: A Workshop to Identify Barriers and Enablers by Johan Van Limbergen, Jennifer Haskett, Anne M Griffiths, Jeff Critch, Hien Huynh, Najma Ahmed, Jennifer C deBruyn, Robert Issenman, Wael El-Matary, Thomas D Walters, Cheryl Kluthe, Marie-Eve Roy, Elizabeth Sheppard, Wallace V Crandall, Stan Cohen, Frank M Ruemmele, Arie Levine, Anthony R Otley

“…In pediatric CD, EEN is now recommended by the pediatric committee of the European Crohn’s and Colitis Organisation and the European Society for Paediatric Gastroenterology Hepatology and Nutrition as a first-choice agent to induce remission, with remission rates in pediatric studies consistently >75%. …”
Get full text

Metabolic Profiling by UPLC–Orbitrap–MS/MS of Liver from C57BL/6 Mice with DSS-Induced Inflammatory Bowel Disease by Zhongquan Xin, Zhenya Zhai, Hongrong Long, Fan Zhang, Xiaojun Ni, Jinping Deng, Lunzhao Yi, Baichuan Deng

“…First, a refined and translationally relevant model of DSS chronic colitis in C57BL/6 mice was established, and cecropin A and antibiotics were used as interventions. …”
Get full text